[go: up one dir, main page]

AR048937A1 - Proceso para preparar bisulfato de atazanavir forma e3 y material de configuracion c - Google Patents

Proceso para preparar bisulfato de atazanavir forma e3 y material de configuracion c

Info

Publication number
AR048937A1
AR048937A1 ARP050101776A ARP050101776A AR048937A1 AR 048937 A1 AR048937 A1 AR 048937A1 AR P050101776 A ARP050101776 A AR P050101776A AR P050101776 A ARP050101776 A AR P050101776A AR 048937 A1 AR048937 A1 AR 048937A1
Authority
AR
Argentina
Prior art keywords
bisulfate
atazanavir
atazanavir bisulfate
crystals
configuration material
Prior art date
Application number
ARP050101776A
Other languages
English (en)
Inventor
Soojin Kim
Bruce T Lotz
Mary F Malley
Jack Z Gougoutas
Martha Davidovich
Sushil K Srivastava
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048937(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR048937A1 publication Critical patent/AR048937A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un proceso para preparar el inhibidor de proteasa del VIH, bisulfato de atazanavir, en donde una solucion de base libre de atazanavir en un solvente orgánico se hace reaccionar con ácido sulfurico concentrado en una cantidad para reaccionar con menos de aproximadamente 15% en peso de la base libre, se adicionan semillas de cristales de Forma A de bisulfato de atazanavir a la mezcla de reaccion, como cristales de la forma de bisulfato, se adiciona ácido sulfurico concentrado adicional en etapas multiples a velocidades incrementadas de acuerdo con una ecuacion cubica, para efectuar la formacion de cristales de Forma A de bisulfato de atazanavir. También se proporciona un proceso para preparar bisulfato de atazanavir como material de configuracion C con un espectro de rayos X, como se muestra en la figura. Una nueva forma de bisulfato de atazanavir también se proporciona la cual es la forma E3 la cual es un solvato de trietanolato altamente cristalino de la sal de bisulfato de etanol caracterizado por su espectro de rayos X, como se muestra en la figura. Formulaciones farmacéuticas que comprenden material de configuracion C, otras que comprenden Forma E3 o Forma A de bisulfato de atazanavir.
ARP050101776A 2004-05-04 2005-05-03 Proceso para preparar bisulfato de atazanavir forma e3 y material de configuracion c AR048937A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56804304P 2004-05-04 2004-05-04
US60753304P 2004-09-07 2004-09-07

Publications (1)

Publication Number Publication Date
AR048937A1 true AR048937A1 (es) 2006-06-14

Family

ID=35320785

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050101777A AR049268A1 (es) 2004-05-04 2005-05-03 Proceso que emplea cristalizacion controlada en la formacion de cristales de un producto farmaceutico.
ARP050101776A AR048937A1 (es) 2004-05-04 2005-05-03 Proceso para preparar bisulfato de atazanavir forma e3 y material de configuracion c

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050101777A AR049268A1 (es) 2004-05-04 2005-05-03 Proceso que emplea cristalizacion controlada en la formacion de cristales de un producto farmaceutico.

Country Status (8)

Country Link
US (1) US20050256314A1 (es)
EP (1) EP1758664A4 (es)
AR (2) AR049268A1 (es)
CL (1) CL2011003144A1 (es)
PE (2) PE20060216A1 (es)
RU (1) RU2385325C2 (es)
TW (3) TWI445697B (es)
WO (1) WO2005108380A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
DK2032521T3 (da) * 2006-06-27 2010-01-25 Sandoz Ag Ny fremgangsmåde til saltfremstilling
EP2178511B1 (en) * 2007-06-22 2011-03-02 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
MX2009013461A (es) * 2007-06-22 2010-01-15 Bristol Myers Squibb Co Composiciones comprimidas que contienen atazanavir.
CN101778625A (zh) * 2007-06-22 2010-07-14 百时美施贵宝公司 含有阿扎那韦的压片组合物
EP2179272B1 (de) * 2007-07-10 2011-03-23 Boehringer Ingelheim International GmbH Optische befuellungskontrolle von pharmazeutischen kapseln auf kapselfuellmaschinen
WO2009014676A1 (en) * 2007-07-23 2009-01-29 Merck & Co., Inc. Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
EP2272830A1 (en) 2009-06-18 2011-01-12 Esteve Química, S.A. Preparation process of an antivirally heterocyclic azahexane derivative
CN104163787A (zh) * 2014-08-08 2014-11-26 山东威智医药工业有限公司 阿扎那韦及其硫酸盐的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940998A (en) * 1953-10-15 1960-06-14 Ajinomoto Kk Process for resolution of racemic glutamic acid and salts thereof
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5428048A (en) * 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
KR20020015030A (ko) * 1999-03-22 2002-02-27 스티븐 비. 데이비스 ｃＧＭＰ 포스포디에스테라제의 접합된 피리도피리다진억제제
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6254888B1 (en) * 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
CZ20011726A3 (cs) * 2000-05-26 2002-02-13 Pfizer Products Inc. Způsob reakční krystalizace, který umoľňuje řídit velikost částic
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法

Also Published As

Publication number Publication date
WO2005108380A2 (en) 2005-11-17
PE20060216A1 (es) 2006-03-17
TW200606142A (en) 2006-02-16
RU2385325C2 (ru) 2010-03-27
AR049268A1 (es) 2006-07-12
CL2011003144A1 (es) 2012-04-13
EP1758664A4 (en) 2010-12-22
WO2005108380A3 (en) 2006-08-24
US20050256314A1 (en) 2005-11-17
EP1758664A2 (en) 2007-03-07
TWI518072B (zh) 2016-01-21
TW200600498A (en) 2006-01-01
RU2006142768A (ru) 2008-06-10
TW201427949A (zh) 2014-07-16
TWI445697B (zh) 2014-07-21
PE20060466A1 (es) 2006-06-01

Similar Documents

Publication Publication Date Title
AR099594A2 (es) Proceso para preparar bisulfato de atazanavir y otras formas
BRPI0509595B8 (pt) processos para a preparação de cristais de forma a e de material de padrão c de bissulfato de atazanavir
AR053412A1 (es) Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
AR048937A1 (es) Proceso para preparar bisulfato de atazanavir forma e3 y material de configuracion c
MX2012001463A (es) Proceso para la fabricacion de compuestos.
UY30282A1 (es) Compuestos quimicos
ECSP056127A (es) Inhibidores de 3-quinasa de fosfatidil-inositol
NI200700064A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos.
UY29300A1 (es) Compuestos quimicos
UY29827A1 (es) 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
UY29261A1 (es) Procedimiento para combatir enfermedades fúngicas en leguminosas
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
CU23515A3 (es) Nuevo proceso para la síntesis y nueva forma cristalina de agomelatina y composiciones farmacéuticas que la contienen
AR098260A2 (es) Polimorfo cristalino de una sal de bisulfato de un antagonista del receptor de trombina, proceso para su preparación, composición y forma purificada
AR065775A1 (es) Procedimiento para preparar 2,6-dicloro-4-(trifluorometil)-fenilhidracina usando mezclas de dicloro-fluoro-trifluorometilbencenos
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
SE0401762D0 (sv) Novel compounds
AR034120A1 (es) Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
UY39197A (es) Mezclas y composiciones que comprenden 5-fluoro-4-imino-3- metil-1-tosil-3,4-dihidropirimidin-2-ona, y métodos de uso de las mismas
DK1989174T3 (da) Substituerede cyclohexylmethyl-derivater
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
PE20110163A1 (es) Proceso para la preparacion de derivados de pirimidina sustituidos
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
AR046229A1 (es) Procesos para la preparacion de cefalosporina 3-(2-vinilo sustituido) altamente pura

Legal Events

Date Code Title Description
FC Refusal